0001193125-21-254013.txt : 20210823 0001193125-21-254013.hdr.sgml : 20210823 20210823162733 ACCESSION NUMBER: 0001193125-21-254013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20210823 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210823 DATE AS OF CHANGE: 20210823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 211197293 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d187995d8k.htm 8-K 8-K
CVS HEALTH Corp false 0000064803 0000064803 2021-08-23 2021-08-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2021

 

 

 

LOGO

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-01011   05-0494040

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One CVS Drive, Woonsocket, Rhode Island   02895
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   CVS   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Section 8 - Other Events

 

Item 8.01.

Other Events

On August 23, 2021, CVS Health Corporation, a Delaware corporation (the “Company”), issued press releases announcing the (A) early results of its previously announced cash tender offer (the “Tender Offer”) and (B) pricing of the Tender Offer. The Tender Offer was upsized by increasing the maximum amount of the Tender Offer to $2,049,919,000 (as increased and amended, the “Maximum Amount”) from $2,000,000,000.

Because the Company expects to accept for purchase the Maximum Amount of Notes, no additional Notes are expected to be purchased pursuant to the Tender Offer after August 24, 2021, the early settlement date for such Notes validly tendered and accepted for purchase by the Company.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, which are incorporated by reference herein.

Section 9 - Financial Statements and Exhibits

 

Item 9.01

Financial Statements and Exhibits

 

(d)

Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS

 

Exhibit

   

Description

99.1    Press Release of CVS Health Corporation dated August 23, 2021
99.2    Press Release of CVS Health Corporation dated August 23, 2021
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CVS HEALTH CORPORATION
Date: August 23, 2021   By:  

/s/ Shawn M. Guertin

    Shawn M. Guertin
    Executive Vice President and Chief Financial Officer
 EX-99.1 2 d187995dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor    Susie Lisa, CFA       Media    T.J. Crawford
Contact:    Senior Vice President       Contact:    Vice President
   Investor Relations          External Affairs
   (401) 770-4050          (212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Early Results and Upsize of Previously Announced Cash Tender Offer

to an Aggregate Principal Amount of $2,049,919,000 from $2,000,000,000

WOONSOCKET, RI, August 23, 2021 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the early results of the previously announced cash tender offer (the “Tender Offer”) and that it is amending the Tender Offer by increasing the aggregate principal amount to $2,049,919,000 (as increased and amended, the “Maximum Amount”) from $2,000,000,000, of its 4.300% Senior Notes due 2028 (the “Notes”).

The Maximum Amount represents the principal amount of the Notes subject to the Tender Offer and excludes any Accrued Interest (as defined below) or Early Tender Payment (as defined below). The Tender Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 9, 2021 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offer. The Tender Offer is open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes.

 

Title of Notes

    CUSIP
Number		      Early Tender
Payment(1)		    Principal
Amount
Outstanding		      Principal
Amount
Tendered		      Principal
Amount
Expected to be
Accepted for
Purchase(2)		  

4.300% Senior Notes due 2028

      126650 CX6      $30    $ 7,049,919,000      $ 3,353,427,000      $ 2,049,919,000  

 

(1)

Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

(2)

After application of proration.

The consideration to be paid in the Tender Offer for the Notes validly tendered and expected to be accepted for purchase as described in the Offer to Purchase (the “Total Consideration”) will be determined at 9:00 a.m., New York City time, on August 23, 2021.

As of 5:00 p.m., New York City time, on August 20, 2021 (the “Early Tender Date”), as reported by D.F. King & Co., Inc., the Tender and Information Agent for the Tender Offer, the principal amount of the Notes listed in the table above have been validly tendered and not validly withdrawn. The Withdrawal Deadline of 5:00 p.m., New York City time, on August 20, 2021 has passed and, accordingly, Notes validly tendered in the Tender Offer may no longer be withdrawn.

CVS Health expects to accept for purchase and make payment for Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date on August 24, 2021 (the “Early Settlement Date”), subject to proration. Because the aggregate principal amount of Notes validly tendered exceeds the Maximum Amount, CVS Health expects that it will accept validly tendered Notes on a prorated basis in accordance with the Offer to Purchase.

Because CVS Health expects to accept for purchase the Maximum Amount of Notes, no additional Notes will be purchased pursuant to the Tender Offer after the Early Settlement Date. As described in the Offer to Purchase, all Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

Holders of all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase are eligible to receive the Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount of Notes tendered at or prior to the Early Tender Date (the “Early Tender Payment”). In addition to the Total Consideration, Holders of Notes accepted for purchase will receive accrued and unpaid interest up to, but not including, the Early Settlement Date (“Accrued Interest”).

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Tender Offer at any time prior to the Expiration Date. The Tender Offer is not conditioned on any minimum principal amount of Notes being tendered but the Tender Offer is subject to certain conditions as described in the Offer to Purchase.

CVS Health has retained Barclays Capital Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC to act as Dealer Managers for the Tender Offer. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offer. Requests for assistance relating to the procedures for tendering Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (800) 549-6746 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offer may be directed to Barclays Capital Inc. at (212) 528-7581 (collect) or (800) 438-3242 (toll free), Goldman Sachs & Co. LLC at (212) 902-5962 (collect) or (800) 828-3182 (toll free) and Wells Fargo Securities, LLC at (704) 410-4759 (collect) or (866) 309-6316 (toll free) or via email at liabilitymanagement@wellsfargo.com. Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offer is being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offer. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offer, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is the leading health solutions company, delivering care in ways no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and our nearly 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 and our recently filed Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

 

2

EX-99.2 3 d187995dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

 

Investor   Susie Lisa, CFA       Media   T.J. Crawford
Contact:   Senior Vice President       Contact:   Vice President
  Investor Relations         External Affairs
  (401) 770-4050         (212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Pricing of Tender Offer

WOONSOCKET, RI, August 23, 2021 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the Reference Yield and Total Consideration (each as summarized in the table below) to be paid in connection with the previously announced cash tender offer (the “Tender Offer”) for up to $2,049,919,000 principal amount (the “Maximum Amount”), of its 4.300% Senior Notes due 2028 (the “Notes”).

The Maximum Amount represents the principal amount of the Notes subject to the Tender Offer and excludes any Accrued Interest (as defined below) or Early Tender Payment (as defined below). The Tender Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 9, 2021 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offer. The Tender Offer is open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes.

The Reference Yield for the Notes and the Total Consideration for the Notes are summarized in the table below:

 

Title of Notes

   

CUSIP
Number

   

UST Reference
Security

   

Fixed Spread
(bps)

   

Reference Yield

   

Total
Consideration(1)

4.300% Senior Notes due 2028

    126650 CX6    1.625% UST due 5/15/2031    35   

1.250%

   

$1,162.08

 

(1)

Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

The Total Consideration for each $1,000 principal amount of the Notes was determined in the manner described in the Offer to Purchase by reference to the fixed spread set forth in the table above plus the yield to maturity of the U.S. Treasury reference security (the “UST Reference Security”) set forth in the table above on the bid-side price of such UST Reference Security as of 9:00 a.m., New York City time, on August 23, 2021.

The Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on August 20, 2021 (the “Early Tender Date”) will be eligible to receive the Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount of Notes.

CVS Health expects to accept for purchase and make payment for Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date on August 24, 2021 (the “Early Settlement Date”).

Holders of all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase are eligible to receive the Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount of Notes tendered at or prior to the Early Tender Date (the “Early Tender Payment”). In addition to the Total Consideration, Holders of Notes accepted for purchase will receive accrued and unpaid interest up to, but not including, the Early Settlement Date (“Accrued Interest”).

Because the aggregate principal amount of Notes validly tendered would exceed the Maximum Amount, CVS Health expects that it will accept validly tendered Notes on a prorated basis in accordance with the Offer to Purchase.

Because CVS Health expects to accept for purchase the Maximum Amount of Notes, no additional Notes will be purchased pursuant to the Tender Offer after the Early Settlement Date. As described in the Offer to Purchase, Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Tender Offer at any time prior to the Expiration Date. The Tender Offer is not conditioned on any minimum principal amount of Notes being tendered but the Tender Offer is subject to certain conditions as described in the Offer to Purchase.

CVS Health has retained Barclays Capital Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC to act as Dealer Managers for the Tender Offer. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offer. Requests for assistance relating to the procedures for tendering Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (800) 549-6746 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offer may be directed to Barclays Capital Inc. at (212) 528-7581 (collect) or (800) 438-3242 (toll free), Goldman Sachs & Co. LLC at (212) 902-5962 (collect) or (800) 828-3182 (toll free) and Wells Fargo Securities, LLC at (704) 410-4759 (collect) or (866) 309-6316 (toll free) or via email at liabilitymanagement@wellsfargo.com. Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offer is being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offer. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offer, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is the leading health solutions company, delivering care in ways no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and our nearly 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 and our recently filed Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

 

2

EX-101.SCH 4 cvs-20210823.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 cvs-20210823_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 cvs-20210823_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g187995g0822060553377.jpg GRAPHIC begin 644 g187995g0822060553377.jpg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end GRAPHIC 8 g187995g0822061032665.jpg GRAPHIC begin 644 g187995g0822061032665.jpg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end GRAPHIC 9 g187995g0822061527615.jpg GRAPHIC begin 644 g187995g0822061527615.jpg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d187995d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2021-08-23 2021-08-23 CVS HEALTH Corp false 0000064803 8-K 2021-08-23 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 23, 2021
Cover [Abstract]  
Entity Registrant Name CVS HEALTH Corp
Amendment Flag false
Entity Central Index Key 0000064803
Document Type 8-K
Document Period End Date Aug. 23, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code (401)
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d187995d8k.htm cvs-20210823.xsd cvs-20210823_lab.xml cvs-20210823_pre.xml d187995dex991.htm d187995dex992.htm g187995g0822061527615.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d187995d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d187995d8k.htm" ] }, "labelLink": { "local": [ "cvs-20210823_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20210823_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cvs-20210823.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20210823", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d187995d8k.htm", "contextRef": "duration_2021-08-23_to_2021-08-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d187995d8k.htm", "contextRef": "duration_2021-08-23_to_2021-08-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com//20210823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-21-254013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-254013-xbrl.zip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